HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: FDA Appropriations

This article was originally published in The Rose Sheet

Executive Summary

FDA Appropriations: Agency's budget would remain level in FY 1996, under a spending bill reported out of the House Appropriations/Agriculture Subcommittee on June 14. The measure provides $917.7 mil. for salaries and expenses. The subcommittee's report language is expected to direct FDA to cut administrative expenses in the commissioner's office for public and international affairs and other areas, and to shift resulting savings to medical device approvals. Language directing cuts in the commissioner's office originally appeared in the spending bill at the request of Rep. Jack Kingston (R-GA), but the Georgia congressman agreed to consider placing the directive in report language after discussions with Ranking Minority Member Richard Durbin (D-IL). Full committee markup is set for June 22...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001727

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel